The effect of S-Adenosyl L-methionine on sexual function of the individuals receiving Methadone Maintenance Treatment:

The Effect of S-Adenosyl-L-Methionine on Sexual Function in Individuals Receiving Methadone Maintenance Treatment: A Double-Blind, Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241216064072N1

Enrollment

Registered

2025-01-01

Start date

2025-01-29

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexual dysfunction. Sexual dysfunction not due to a substance or known physiological condition

Interventions

Intervention 1: Intervention group: The intervention group will undergo treatment with SAM-e. The duration of medication use for the intervention group is 6 weeks. Participants in this group will rece

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Individuals aged 18 to 65 years Individuals receiving Methadone Maintenance Treatment (MMT) Stable methadone dosage for more than 8 weeks Having provided informed consent to participate in the study No concurrent use of any other substances alongside methadone

Exclusion criteria

Exclusion criteria: A history of major psychiatric disorders (e.g., depression, bipolar disorder, etc.) based on DSM-5 criteria prior to the initiation of Methadone Maintenance Treatment A history of unstable non-psychiatric conditions such as diabetes, hypertension, epilepsy, endocrine disorders, and neurological disorders The use of medications such as Antihypertensives, Antidepressants (especially MAOIs), Sedatives, Anticholinergics or Antipsychotics, Anti-HIV drugs, Tuberculosis and Hepatitis medications, Amphetamines, Dextromethorphan, Levodopa, Narcotics, and Hypericum Perforatum Androgen replacement therapy, Phosphodiesterase-5 inhibitors, or any treatment that may induce changes in sleep health, sexual function, or mood Occurrence and intolerance of side effects (e.g., nausea, diarrhea or constipation, mild insomnia, dizziness, irritability, anxiety, and sweating) during medication use Lack of patient cooperation or consent during the study

Design outcomes

Primary

Measure	Time frame
The sexual function score in the Male Sexual Function Questionnaire(MSFQ) and the Female Sexual Function Index (FSFI). Timepoint: Before the start of the study and 6 weeks after initiating medication. Method of measurement: Male Sexual Function Questionnaire(MSFQ) and Female Sexual Function Index (FSFI).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTahereh Dezham

University of social welfare and rehabilitation sciences

tahereh.d2010@gmail.com+98 917 730 7380

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026